Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Jefferies Global Healthcare Conference in New York from June 4-6, 2024.



Aurinia

Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
Agilent Reports Second-Quarter Fiscal Year 2024 Financial ResultsPhoto, wide shot, wide-angle lens, soft focus,  Amusement park, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-9ykfBOFTwqbOHnaukQ2bUqdm.png?st=2023-05-13T13%3A50%3A52Z&se=2023-05-13T15%3A50%3A52Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-12T20%3A43%3A22Z&ske=2023-05-13T20%3A43%3A22Z&sks=b&skv=2021-08-06&sig=G2Gltvd1Lg2exXRILeKuP5%2BTSWMna0SOjxb75jCyrG0%3D
Agilent Reports Second-Quarter Fiscal Year 2024 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core(1) compared to the second quarter

Chemed Corporation to Present at the Jefferies 2024 Global Healthcare Conference:
Chemed Corporation to Present at the Jefferies 2024 Global Healthcare Conference


Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024, at approximately 9:00 a.m. (ET) at

Savara to Present at the Jefferies Global Healthcare Conference: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Present at the Jefferies Global Healthcare Conference


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the

Vistagen to Present at the Jefferies Global Healthcare Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at the Jefferies Global Healthcare Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth

EQS-News: BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
EQS-News: BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
EQS-News: BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
Owens & Minor to Present at the Leerink Partners’ Healthcare Crossroads Conference on May 29, 2024: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor to Present at the Leerink Partners’ Healthcare Crossroads Conference on May 29, 2024


Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution

Puma Biotechnology to Join Russell 3000 Index: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Join Russell 3000 Index


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments’ annual reconstitution of its

Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024


Regulatory News:



Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

EQS-News: BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 
EQS-News: BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 
EQS-News: BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 
EQS-News: MeVis publishes figures for the first half of fiscal year 2023/2024
EQS-News: MeVis publishes figures for the first half of fiscal year 2023/2024
EQS-News: MeVis publishes figures for the first half of fiscal year 2023/2024
TIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
TIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland


Novocure (NASDAQ: NVCR) hat heute die ersten Wirksamkeits- und Sicherheitsdaten der TIGER-Studie veröffentlicht, die den Einsatz der Therapie mit Tumor Treating Fields (TTFields) in der klinischen

EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany


Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual

Agilent Announces Hans E. Bishop Has Stepped Down from Board of Directors:
Agilent Announces Hans E. Bishop Has Stepped Down from Board of Directors


Agilent Technologies Inc. (NYSE: A) today announced that Hans E. Bishop, president and co-founder of Altos Labs, has stepped down from serving on Agilent’s board of directors.



Bishop joined

LivaNova to Present at the Goldman Sachs Healthcare Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present at the Goldman Sachs Healthcare Conference


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs

Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence:
Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence


Agilent Technologies Inc., (NYSE: A) proudly announces the 8850 Gas Chromatograph (GC) System, a small single-channel GC that combines the legacy of the 6850 GC with the capability and system

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Participate in 44th Annual William Blair Growth Stock Conference


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors
Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors
Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors
EQS-News: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
EQS-News: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
EQS-News: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024